Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 180

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation

Raichlin, Eugenia, Bae, Jang-Ho, Khalpey, Zain, Edwards, Brooks S., Kremers, Walter K., Clavell, Alfredo L., Rodeheffer, Richard J., Frantz, Robert P., Rihal, Charanjit, Lerman, Amir, Kushwaha, Sudhir S. · 2007 · Circulation

Abstract

Background— We investigated the potential of conversion to sirolimus (SRL) as a primary immunosuppressant in attenuating cardiac allograft vasculopathy progression. Methods and Results— Twenty-nine cardiac transplant recipients were converted to SRL 3.8±3.4 years after transplantation with complete calcineurin inhibitor (CNI) withdrawal. Secondary immunosuppressants (azathioprine or mycophenolate) and steroids remained unchanged. Forty patients (controls) 4.8±4.0 years from transplantation were maintained on CNIs. Three-dimensional intravascular ultrasound studies were performed at baseline and 12.1±2.6 months later. Mean plaque (media and intima) volume (PV) and plaque index (PI) (PV/vessel volume percent) increased significantly in the CNI group (1.28±2.86 mm 3 /mm, P =0.004; and 6±8%, P =0.0001) but not in the SRL group (0.1±1.13 mm 3 /mm, P =0.63; and 0.1±8%, P =0.94). In patients enrolled within 2 years after transplantation, the increases in PV (0.06±1.06 versus 1.77±1.65 mm 3 /mm; P =0.0081) and PI (0±9% versus 10±8%; P =0.0145) were smaller in the SRL group (n=11) than in the CNI (n=12) group. In patients enrolled ≥2 years after transplantation, the increase in PI was less in the SRL group compared with the CNI group (0.1±6.5% versus 5±8%; P =0.033), but changes in PV did not differ significantly. Treatment with azathioprine or mycophenolate did not affect PV or PI in either the SRL group (PV: 0.22±0.66 versus 0.05±1.45 mm 3 /mm, P =0.46; PI: 1.5±6% versus −1.6±8.5%, P =0.29) or the CNI group (PV: 1.42±1.39 versus 1.06±2.28 mm 3 /mm, P =0.49; PI: 7.8±8.7% versus 4.8±7.3%, P =0.23). Conclusions— Substituting CNI with SRL as primary immunosuppression attenuates cardiac allograft vasculopathy progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.107.692996

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 180

Metadata

Authors
Raichlin, E., Bae, J.-H., Khalpey, Z., Edwards, B. S., Kremers, W. K., Clavell, A. L., Rodeheffer, R. J., Frantz, R. P., Rihal, C., Lerman, A., & Kushwaha, S. S.
Venue
Circulation
Published
2007-12-04
Volume
116
Issue
23
Pages
2726-2733
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2054627746
Cited by
180
References
1
FWCI
13.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation. https://app.cochat.ai/papers/10.1161/circulationaha.107.692996
The paper
Raichlin, E., Bae, J.-H., Khalpey, Z., Edwards, B. S., Kremers, W. K., Clavell, A. L., Rodeheffer, R. J., Frantz, R. P., Rihal, C., Lerman, A., & Kushwaha, S. S. (2007). Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation. Circulation. https://doi.org/10.1161/circulationaha.107.692996

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.